Trial Profile
Randomized, Double-Blind, Phase 2 Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Merestinib (Primary) ; Ramucirumab (Primary) ; Cisplatin; Gemcitabine
- Indications Adenocarcinoma; Biliary cancer; Carcinoma; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
- 17 Jan 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2025.
- 28 Jan 2023 This trial has been discontinued in Italy according to European Clinical Trials Database record.
- 18 Oct 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.